Spotlight On... New study IDs a fresh approach on fighting AML; New screening method for antibiotics; Biologic markers found for mental disorders; 'Failed' drug shows promise for bipolar disorder; and more...

Two molecules--Hif-1alpha and Hif-2alpha--work together to stop the formation of leukemic stem cells in acute myeloid leukemia, according to a new study from the University of Edinburgh. "Our discovery that Hif-1alpha and Hif-2alpha molecules act together to stop leukemia development is a major milestone in our efforts to combat leukemia," said Professor Kamil R Kranc, Cancer Research UK Senior Fellow at the MRC Centre for Regenerative Medicine. "We now intend to harness this knowledge to develop curative therapies that eliminate leukemic stem cells, which are the underlying cause of AML." Release

> Biologists at UC San Diego say they have developed a new method to identify and "characterize new antibiotics can be employed to screen natural products quickly for compounds capable of controlling antibiotic resistant bacteria." Release

> Researchers at the University of Georgia say they have found biological markers that make it possible to classify mental disorders with greater precision. Release

> Reviewing a list of "failed" drugs, Oxford scientists say that the stroke drug ebselen demonstrated promise as a replacement therapy for bipolar disorder. Release

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.